van der Velden Yme U, Villaudy Julien, Siteur-van Rijnstra Esther, van der Linden Cynthia A, Frankin Esmay, Weijer Kees, Schermer Edith, Vink Monique A, Berkhout Ben, Sanders Rogier W, van Gils Marit J
1 Laboratory of Experimental Virology, Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam , Amsterdam, the Netherlands .
2 AIMM Therapeutics , Amsterdam, the Netherlands .
AIDS Res Hum Retroviruses. 2018 Sep;34(9):790-793. doi: 10.1089/AID.2018.0114. Epub 2018 Aug 22.
Broadly neutralizing antibodies (bNAbs) such as PGDM1400 show promise as prophylactic and therapeutic agents against HIV-1. Human immune system mice were passively immunized with different doses of PGDM1400 and challenged 24 h later with a high dose of HIV-1. We found that PGDM1400 provided protection against HIV-1 challenge in a concentration dependent manner and that the protective concentration in blood was ∼75-fold higher than the in vitro 50% inhibitory concentration. The results demonstrate that PGDM1400 might be a promising component of strategies to prevent HIV-1 infection and provide support for the pursuit of vaccines that induce PGDM1400-like bNAbs.
诸如PGDM1400之类的广泛中和抗体（bNAbs）有望成为抗HIV-1的预防和治疗药物。用不同剂量的PGDM1400对人免疫系统小鼠进行被动免疫，并在24小时后用高剂量的HIV-1进行攻击。我们发现PGDM1400以浓度依赖的方式提供针对HIV-1攻击的保护作用，并且血液中的保护浓度比体外50%抑制浓度高约75倍。结果表明，PGDM1400可能是预防HIV-1感染策略的一个有前景的组成部分，并为研发诱导PGDM1400样bNAbs的疫苗提供了支持。
